Illustrative image – not actual.Orchid Chemicals & Pharmaceuticals has
formed an equal joint venture with California-based Bexel Biotechnology, for
drug research.
The company will focus on developing new drugs for
diabetes, obesity and inflammation, which it hopes to license out to global
drug manufacturers.
Over the next 3 years, Orchid plans to invest US$ 8 million
(approx. Rs.38 crore) as equity in the California-based joint venture, Bexel
Pharmaceuticals. During 2002-03, the company plans to invest a total of US$ 2
million (approx. Rs.10 crore) and US$ 3 million (approx. Rs.14 crore) each in
the following 2 years.
